公开(公告)号：US12006331B2

公开(公告)日：2024-06-11

申请号：US17862963

申请日：2022-07-12

Applicant: GENENTECH, INC.

Inventor： Samantha Alyson Green ,  Jessica Marie Grandner ,  Steven Thomas Staben ,  Neri Amara ,  Vishva M. Dixit ,  Elisia Villemure

IPC: C07D498/04 ,  A61K9/08 ,  A61K9/12 ,  A61K9/20 ,  A61K9/48 ,  A61K47/02 ,  A61K47/06 ,  A61K47/10 ,  A61K47/12 ,  C07D519/00 ,  C07F9/6561

CPC classification number: C07D498/04 ,  A61K9/08 ,  A61K9/12 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866 ,  A61K47/02 ,  A61K47/06 ,  A61K47/10 ,  A61K47/12 ,  C07D519/00 ,  C07F9/6561

Abstract: The invention provides a compound of formula (I):




or a prodrug thereof, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 have any of the values described in the specification, as well as compositions comprising a compound of formula (I) or a prodrug thereof, or a pharmaceutically acceptable salt thereof. The compounds are agonists of glycolytic enzyme phosphofructokinase-1 liver type and are useful for treating diseases associated with the activity of glycolytic enzyme phosphofructokinase-1 liver type, such as cancer, diabetes, sepsis, and septic shock.